Marvin Herzberger
Marvin Herzberger is a publishing trader at TraderFox GmbH and group leader for the technical analysis of the DAX. He has been actively engaged in technical analysis since 2011. In this context, he has tested, analyzed, and evaluated various trading strategies in practical implementation. His area of expertise lies in swing trading. The analyses cover a short-term time horizon of up to 10 days.
Latest from Marvin Herzberger
Regeneron: Billion-Dollar Deal with Sanofi and New Approvals Secure Market Position
Revenue climbed in the third quarter to $5.1 billion, driven by sales figures for Dupixent and Eylea...
Dexcom: New Addressed Customer Segments, Margin Increase, and $1 Billion Share Buyback Shape Q3!
Sales in Q3 2026 increase by 11% year-on-year to $1.34 billion. The gross margin reaches 65.1%, a...
PTC Therapeutics: Will the Long-Term Market Penetration with the Drug Sephience Succeed? Experts See 74% Price Potential!
The biotechnology company PTC Therapeutics is benefiting from robust revenue growth driven by the drug...
Genmab: Leader in the European healthcare sector impresses with study data and fresh all-time high!
Genmab has been a frequent topic of discussion since early August, as the healthcare company focused...
Replimune: Leerink Analyst Sees Over 80% Price Potential After Quarterly Results
Replimune undergoes a transformation into a commercial company focused on the oncology product TUDRIQEV....
Impinj: New M800 Chip Drives Gross Margin Above 52%!
Revenue growth in Q3 2026 of 16.7% to $112.1 million driven by strong IC sales. An improved gross...
Crocs: Asia Expansion and Jibbitz Sales Support Revised Outlook Scenario 2026
The shift to direct-to-consumer channels and international markets secures continuous growth for the...
IBM: Increased Cash Flow Forecast Meets Unforeseen Caution Regarding Customer AI Budgets
IBM's quarterly revenue recently increased by 5%, driven by strong growth in the software and data sectors....
C4 Therapeutics: $11 Price Target from Lake Street Highlights Triple Strategy in Multiple Myeloma
C4 Therapeutics utilizes targeted protein degradation for cancer treatment and advances the clinical...
SoFi Technologies: 17 Million Users Pave the Way for Sustainable Profit Growth!
SoFi Technologies (SOFI) (i.) offers its customers an integrated financial platform, combining lending,...
GE HealthCare: Stable Investment Willingness of Clinics Meets Pricing Power and Cost Control
Quarterly revenue increased organically by 6.2% to $5.51 billion. The adjusted operating margin improved...
Flex Ltd.: Axiom spin-off and EPC acquisition reshape corporate structure
Revenue rose by 25% to $8.5 billion in Q2 2027 due to AI demand. The spin-off of the cloud and power...
Immunome: Regulatory filings and new study data - H.C. Wainwright sees 112% price potential!
ESMO data demonstrate sustainable relief in aggressive desmoid tumors. Analysts see a price target...
Johnson Controls International: Data Center Expansion Leads to Full Order Books!
Johnson Controls International (JCI) was able to attract investors' attention with the quarterly numbers...
Johnson Controls: Demand for Climate Technology and Data Centers Leads to Record Backlog of $23 Billion!
Strong organic revenue growth of 12% in Q4 2026, driven by demand for climate technology and data centers....
Kiniksa Pharmaceuticals: Arcalyst Success Drives Net Income Up Over 150% - Stock Price Aims for All-Time High!
Revenue Surge: Revenues in Q3 increased by approximately 58% due to strong demand for the drug Arcalyst....
Corcept Therapeutics: FDA Decision in December - The Catalyst for the $165 Price Target?
Analysts at Piper Sandler confirm the buy recommendation for Corcept Therapeutics with a price target...
Adesso: Overlooked AI Winner from the Ruhr Area? I Expect Significantly Higher Prices!
The Dortmund-based Adesso SE (i.) is, in my opinion, one of the currently overlooked beneficiaries of...
CACI International: US Navy contract in the field of electromagnetic warfare worth $281 million strengthens strategic direction!
CACI recorded an 8.2% increase in revenue to $2.5 billion in the first quarter of fiscal year 2027....
Nutanix: "Rule of 50" Becomes Tangible by 2029 - Guggenheim Recommends Buying!
Nutanix benefits from its role as an enterprise alternative for migrating VMware customers. Guggenheim...